

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 76813

Title: NF_KB: A novel therapeutic pathway for gastroesophageal reflux disease?

Provenance and peer review: Unsolicited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 00724464

Position: Editorial Board

Academic degree: PhD

Professional title: Associate Professor

Reviewer's Country/Territory: Brazil

Author's Country/Territory: China

Manuscript submission date: 2022-04-01

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-04-05 13:41

Reviewer performed review: 2022-04-05 13:52

Review time: 1 Hour

Scientific quality	[] Grade A: Excellent [] Grade B: Very good [Y] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[] Grade A: Priority publishing [] Grade B: Minor language polishing [Y] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	 [] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection
Re-review	[] Yes [Y] No
Peer-reviewer	Peer-Review: [Y] Anonymous [] Onymous



Baishideng **Publishing**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-399-1568 E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The manuscript NFκB: A novel therapeutic pathway for gastroesophageal reflux disease? aimed to review the pathogenesis of GERD and the relationship between NFKB and GERD, in order to provide new strategies for the treatment of GERD. I can comment that: 1) The review was well conducted and the topic is interesting. I make the suggestion to include in the introduction of the effects of reflux also in the oral cavity and teeth (observe and add: DOI: 10.1080/17474124.2021.1890030); 2) Conduct English language review



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 76813

Title: NF_KB: A novel therapeutic pathway for gastroesophageal reflux disease?

Provenance and peer review: Unsolicited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05548742

Position: Peer Reviewer

Academic degree: MD, PhD

Professional title: Assistant Professor

Reviewer's Country/Territory: Japan

Author's Country/Territory: China

Manuscript submission date: 2022-04-01

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-04-11 02:10

Reviewer performed review: 2022-04-24 09:54

Review time: 13 Days and 7 Hours

Scientific quality	[] Grade A: Excellent [] Grade B: Very good [Y] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	 [] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	 [] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection
Re-review	[Y]Yes []No
Peer-reviewer	Peer-Review: [Y] Anonymous [] Onymous



Baishideng **Publishing**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

In this manuscript, authors show the pathogenesis of GERD and the relationship between NFKB and GERD. This manuscript is well written, and provides an objective presentation of the literature, and the data are presented logically. However, while interesting, there is no clear explanation outlining the advantages of the author's work in comparison to those previously reported studies. It would be an overstatement to use "novel" in the title. As the author also states, this have been shown to be effective in animal studies, and there is no clear clinical data, so there is no novelty. If possible, I would like to include the possibility that authors can present from their recent research.